Weight-loss drug Tirzepatide may reduce risk of type 2 diabetes by 94% in three-year study, Elli Lilly says
Tirzepatide may reduce the risk of type 2 diabetes by 94% Eli Lilly, which makes obesity and diabetes drugs Zepbound and Mounjaro, said the drugs can reduce the risk of developing type 2 diabetes by 94 percent in prediabetic adults who were overweight or obese after three years of weekly injections. Mounjaro and Zepbound both … Read more